MagPro R20+
Our customers can always expect the highest quality
Researchers and clinicians often use MagVenture’s products in combination with products from other manufacturers. Our products are highly integrable with the solutions offered by Localite (neuronavigation), Brain Products (EEG) and Axilum Robotics (TMS Robots)
The R20+ is pulsewidth optimized for higher frequency and more intense stimulation. This allows for a close resemblance of the dynamics of the nervous system; thus, adding even more possibilities within diagnostics and disease monitoring of the central and peripheral nervous system, based on the use of Motor Evoked Potential. The hardware of the R20+ allows for even more aggressive provocation of the neuro- muscular and the neuro-sensory systems, thereby enabling a deeper and more realistic functional activation. Standard rTMS protocols for depression therapy can be done as well.
features
| Max repetition rate | 100 pps |
| Pulse mode | Standard |
| Waveform | Biphasic |
| Current direction | Normal |
| Ramp up | No |
Specifications
Mechanical Data
| HxWxD | 150 x 390 x 440mm/ 5,9 x 15,3 x 17,3 in |
| Weight | 17 kg/ 37.5 lbs |
Coil compatibility
| These coils can be used to operate the MagPro R20+: C-100, C-B60, C-B70, MC-B70, MC-125, MMC-90, MMC-140, MMC-140-II, RT-120, RT-120-II, D-B80, MC-B65-HO, MCF-B65, MCF-B70, MCF-75, MCF-125, MCF-P-B65, MC-P-B70, MCF-P-B70 |
Environmental Data
| Operating temperature | 10-30°C/50-86°F |
| Storage temperature | 5-50°C/41-122°F |
| Operating humidity | 30-60% RH |
| Storage humidity | 20-80% RH |
Power Supply
| Mains voltage | 120V~/230V~,50/60 Hz according to IEC 60601-1 |
| Maximum power consumption | 900 VA |
Ordering number
| 9016E0881 |
Applications
Intended use
Diagnostic Use
The MagPro R20+ is intended as an electro-physiological aid to assess diagnosis and to monitor diseases of the central and peripheral nervous system, based on the use of Motor Evoked Potentials (MEP).
Therapeutic Use
Treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode.
